Benzinga's Top Downgrades

Analysts at Bank of America downgraded Quest Diagnostics (NYSE: DGX ) from “buy” to “underperform.” The target price for Quest Diagnostics has been lowered from $64 to $55. Quest Diagnostics' shares closed at $60.33 yesterday. Morgan Stanley downgraded Home Properties (NYSE: HME ) from “equal-weight” to “underweight.” The